Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:00:38 EDT Mon 30 Jun 2025
Enter Symbol
or Name
USA
CA



Q:IMVT - IMMUNOVANT INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IMVT - Q0.114.22·16.509.916.00-0.10-0.6923.914,24110,40716.14  16.34  15.8034.47  12.7217:31:26May 2915 min RT 2¢

Recent Trades - Last 10 of 10407
Time ETExPriceChangeVolume
17:31:26Q15.6887-0.411346
17:26:13Q15.74-0.369
17:26:13Q15.71-0.3912
17:25:42Q15.77-0.339
17:25:42Q15.75-0.354
17:25:42Q15.74-0.3621
17:02:00Q15.77-0.3329
16:47:35Q15.77-0.3329
16:37:02Q15.77-0.33100
16:37:02Q15.77-0.3329

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-29 07:00U:IMVTNews ReleaseImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
2025-04-21 07:00U:IMVTNews ReleaseImmunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
2025-03-19 07:45U:IMVTNews ReleaseImmunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
2025-03-18 16:32U:IMVTNews ReleaseImmunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
2025-02-06 06:30U:IMVTNews ReleaseImmunovant Reports Financial Results for the Quarter Ended December 31, 2024
2025-01-13 08:00U:IMVTNews ReleaseImmunovant Announces $450 Million Private Placement
2024-11-07 06:30U:IMVTNews ReleaseImmunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
2024-10-29 06:30U:IMVTNews ReleaseImmunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
2024-09-09 07:00U:IMVTNews ReleaseRoivant Provides Update on Graves' Disease Development Program
2024-09-09 03:55U:IMVTNews ReleaseImmunovant Provides Update on Graves' Disease Development Program
2024-09-05 06:30U:IMVTNews ReleaseImmunovant to Host Graves' Disease Program Update on September 9, 2024
2024-08-06 16:05U:IMVTNews ReleaseImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024